6 studies found for:    alzheimer's genentech
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
Condition: Alzheimer's Disease
Interventions: Drug: MABT5102A;   Drug: placebo
2 Completed A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: anti-Abeta;   Drug: placebo
3 Recruiting A Study of Crenezumab Versus Placebo in Preclinical PSEN1 E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer Disease, Including a Placebo-Treated Noncarrier Cohort.
Condition: Alzheimer Disease
Interventions: Drug: crenezumab;   Drug: placebo
4 Completed A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: MABT5102A;   Drug: placebo
5 Active, not recruiting A Long-Term Safety Extension Study of Studies ABE4869g And ABE4955g in Patients With Mild To Moderate Alzheimer's Disease Treated With Crenezumab
Condition: Alzheimer Disease
Intervention: Drug: crenezumab
6 Recruiting A Study of Crenezumab in Patients With Mild to Moderate Alzheimer Disease (AD)
Condition: Alzheimer Disease
Interventions: Drug: crenezumab dose level 1;   Drug: crenezumab dose level 2;   Drug: placebo dose level 1;   Drug: placebo dose level 2

Indicates status has not been verified in more than two years